Alder BioPharmaceuticals Company Profile (NASDAQ:ALDR)

About Alder BioPharmaceuticals

Alder BioPharmaceuticals logoAlder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ALDR
  • CUSIP:
Key Metrics:
  • Previous Close: $22.45
  • 50 Day Moving Average: $22.013
  • 200 Day Moving Average: $26.740
  • 52-Week Range: $15.82 - $36.48
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.63
  • P/E Growth: -0.320
  • Market Cap: $1.09B
  • Outstanding Shares: 50,296,000
  • Beta: 2.61
Profitability:
  • Return on Equity: -32.77%
  • Return on Assets: -31.60%
Debt:
  • Current Ratio: 25.55%
  • Quick Ratio: 25.50%
Additional Links:
Companies Related to Alder BioPharmaceuticals:

Analyst Ratings

Consensus Ratings for Alder BioPharmaceuticals (NASDAQ:ALDR) (?)
Ratings Breakdown: 9 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $42.50 (95.40% upside)

Analysts' Ratings History for Alder BioPharmaceuticals (NASDAQ:ALDR)
Show:
DateFirmActionRatingPrice TargetDetails
1/9/2017Jefferies Group LLCReiterated RatingBuy$46.00View Rating Details
12/18/2016Leerink SwannReiterated RatingOutperformView Rating Details
12/9/2016BMO Capital MarketsReiterated RatingOutperform$42.00View Rating Details
11/24/2016AegisSet Price TargetBuy$41.00View Rating Details
11/25/2016Piper Jaffray CompaniesSet Price TargetBuy$47.00View Rating Details
11/22/2016Credit Suisse GroupReiterated RatingBuy$38.00View Rating Details
9/30/2016Brean CapitalInitiated CoverageBuy$45.00View Rating Details
9/13/2016J P Morgan Chase & CoInitiated CoverageOverweight$40.00View Rating Details
4/21/2016Wells Fargo & CompanyInitiated CoverageOutperformView Rating Details
(Data available from 2/22/2015 forward)

Earnings

Earnings History for Alder BioPharmaceuticals (NASDAQ:ALDR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/23/2017($0.90)N/AView Earnings Details
10/27/2016Q3($0.85)($0.70)ViewListenView Earnings Details
7/26/2016Q2($0.75)($0.79)$1.14 million$0.11 millionViewListenView Earnings Details
4/28/2016Q1($0.72)($0.76)$0.14 millionViewN/AView Earnings Details
2/23/2016Q4($0.65)($0.60)ViewListenView Earnings Details
11/5/2015Q315($0.51)($0.62)$0.23 millionViewN/AView Earnings Details
8/5/2015Q215($0.40)($0.46)$0.23 millionViewN/AView Earnings Details
5/7/2015Q115($0.39)($0.40)ViewListenView Earnings Details
3/4/2015Q414$0.21($0.22)$5.70 million$6.40 millionViewN/AView Earnings Details
11/3/2014Q314$0.05$0.88$14.84 million$38.75 millionViewN/AView Earnings Details
8/5/2014Q2($0.25)($0.40)$5.00 million$4.70 millionViewN/AView Earnings Details
6/18/2014Q1($5.38)$4.60 million$4.80 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Alder BioPharmaceuticals (NASDAQ:ALDR)
Current Year EPS Consensus Estimate: $-3.13 EPS
Next Year EPS Consensus Estimate: $-3.86 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.74)($0.66)($0.71)
Q2 20162($0.80)($0.78)($0.79)
Q3 20162($0.89)($0.87)($0.88)
Q4 20162($0.95)($0.93)($0.94)
Q1 20171($0.98)($0.98)($0.98)
Q2 20171($1.02)($1.02)($1.02)
Q3 20171($1.02)($1.02)($1.02)
Q4 20171($1.02)($1.02)($1.02)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Alder BioPharmaceuticals (NASDAQ:ALDR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Alder BioPharmaceuticals (NASDAQ:ALDR)
Insider Ownership Percentage: 11.50%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/18/2017Mark James LittonInsiderSell1,498$23.10$34,603.80View SEC Filing  
1/9/2017Mark James LittonInsiderSell9,516$23.01$218,963.16View SEC Filing  
12/1/2016Jeffrey T. L. SmithVPSell3,000$22.78$68,340.00View SEC Filing  
12/1/2016John A. LathamInsiderSell3,636$22.78$82,828.08View SEC Filing  
11/7/2016Randall C SchatzmanCEOSell10,000$25.16$251,600.00View SEC Filing  
10/17/2016Mark James LittonInsiderSell6,000$27.50$165,000.00View SEC Filing  
10/3/2016Jeffrey T L SmithVPSell3,000$31.14$93,420.00View SEC Filing  
10/3/2016John A LathamInsiderSell10,000$31.32$313,200.00View SEC Filing  
10/3/2016Randall C SchatzmanCEOSell8,181$31.15$254,838.15View SEC Filing  
9/1/2016Jeffrey T L SmithVPSell3,000$32.49$97,470.00View SEC Filing  
9/1/2016Randall C SchatzmanInsiderSell10,000$32.48$324,800.00View SEC Filing  
8/15/2016Jeffrey T L SmithVPSell3,000$31.17$93,510.00View SEC Filing  
8/1/2016John A LathamInsiderSell10,000$31.19$311,900.00View SEC Filing  
7/27/2016John A LathamInsiderSell10,000$30.14$301,400.00View SEC Filing  
7/25/2016Randall C SchatzmanInsiderSell10,000$28.08$280,800.00View SEC Filing  
6/13/2016Mark James LittonInsiderSell6,000$28.94$173,640.00View SEC Filing  
6/3/2016Jeffrey T L SmithVPSell16,090$30.20$485,918.00View SEC Filing  
6/1/2016John A LathamInsiderSell10,000$30.02$300,200.00View SEC Filing  
5/31/2016Mark James LittonInsiderSell25,000$30.05$751,250.00View SEC Filing  
5/27/2016John A LathamInsiderSell6,401$30.05$192,350.05View SEC Filing  
5/24/2016Randall C SchatzmanCEOSell10,000$28.02$280,200.00View SEC Filing  
4/18/2016Randall C SchatzmanCEOSell30,000$28.07$842,100.00View SEC Filing  
1/4/2016Mark James LittoninsiderSell25,000$31.40$785,000.00View SEC Filing  
1/4/2016Randall C. SchatzmanCEOSell10,000$31.47$314,700.00View SEC Filing  
12/1/2015Jeffrey T. L. SmithVPSell4,272$37.24$159,089.28View SEC Filing  
12/1/2015John A. LathaminsiderSell4,550$37.24$169,442.00View SEC Filing  
12/1/2015Randall C. SchatzmanCEOSell10,000$37.24$372,400.00View SEC Filing  
11/30/2015Stephen M DowDirectorSell88$37.11$3,265.68View SEC Filing  
11/2/2015Jeffrey T. L. SmithVPSell3,900$33.67$131,313.00View SEC Filing  
11/2/2015John A. LathaminsiderSell4,545$33.69$153,121.05View SEC Filing  
11/2/2015Randall C. SchatzmanCEOSell10,000$33.71$337,100.00View SEC Filing  
10/1/2015Jeffrey T. L. SmithVPSell3,900$32.25$125,775.00View SEC Filing  
10/1/2015John A. LathaminsiderSell4,545$32.26$146,621.70View SEC Filing  
9/1/2015Jeffrey T. L. SmithVPSell3,900$38.50$150,150.00View SEC Filing  
9/1/2015John A. LathaminsiderSell4,545$38.52$175,073.40View SEC Filing  
8/31/2015Stephen M DowDirectorSell16,218$38.75$628,447.50View SEC Filing  
6/12/2015Larry BenedictVPSell25,454$47.46$1,208,046.84View SEC Filing  
6/4/2015John A LathamInsiderSell25,000$44.18$1,104,500.00View SEC Filing  
6/1/2015Jeffrey T L SmithVPSell3,900$41.53$161,967.00View SEC Filing  
6/1/2015John A LathamInsiderSell4,545$41.53$188,753.85View SEC Filing  
5/22/2015Jeffrey T L SmithVPSell61,818$38.86$2,402,247.48View SEC Filing  
5/21/2015Stephen M DowDirectorSell20,000$65.69$1,313,800.00View SEC Filing  
5/20/2015Stephen M DowDirectorSell8,462$40.39$341,780.18View SEC Filing  
5/18/2015Clay B SiegallDirectorSell38,181$37.62$1,436,369.22View SEC Filing  
4/1/2015Jeffrey T L SmithVPSell3,900$27.43$106,977.00View SEC Filing  
4/1/2015John A LathamInsiderSell19,045$29.54$562,589.30View SEC Filing  
3/30/2015John A LathamInsiderSell14,500$30.20$437,900.00View SEC Filing  
1/27/2015Jeffrey T L SmithVPSell3,900$28.01$109,239.00View SEC Filing  
1/27/2015John A LathamInsiderSell15,045$28.33$426,224.85View SEC Filing  
1/27/2015Randall C SchatzmanCEOSell100,000$28.42$2,842,000.00View SEC Filing  
1/26/2015Jeffrey T L SmithVPSell2,700$27.89$75,303.00View SEC Filing  
1/26/2015Mark James LittonInsiderSell5,200$28.03$145,756.00View SEC Filing  
1/26/2015Randall C SchatzmanCEOSell36,422$27.93$1,017,266.46View SEC Filing  
11/24/2014Jeffrey T L SmithVPSell29,090$16.08$467,767.20View SEC Filing  
5/13/2014A/S NovoInsiderBuy550,000$10.00$5,500,000.00View SEC Filing  
5/13/2014Alan Bruce MontgomeryDirectorBuy3,000$10.00$30,000.00View SEC Filing  
5/13/2014West 8 Limited Partne VenturesMajor ShareholderBuy250,000$10.00$2,500,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Alder BioPharmaceuticals (NASDAQ:ALDR)
DateHeadline
globenewswire.com logoAlder BioPharmaceuticals to Host Conference Call to Discuss Fourth Quarter and Full Year 2016 Financial and ... - GlobeNewswire (press release) (NASDAQ:ALDR)
globenewswire.com - February 18 at 3:26 PM
News IconAlder BioPharmaceuticals to Host Conference Call to Discuss Fourth Quarter and Full Year 2016 Financial and ... - EconoTimes (NASDAQ:ALDR)
www.econotimes.com - February 16 at 8:07 AM
finance.yahoo.com logoAlder BioPharmaceuticals to Host Conference Call to Discuss Fourth Quarter and Full Year 2016 Financial and Operating Results (NASDAQ:ALDR)
finance.yahoo.com - February 16 at 8:06 AM
News IconKeeping an Eye on Shares of Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) - Midway Monitor (NASDAQ:ALDR)
midwaymonitor.com - February 14 at 4:04 PM
finance.yahoo.com logoAlder BioPharmaceuticals to Present at the Leerink Partners 6th Annual Global Healthcare Conference (NASDAQ:ALDR)
finance.yahoo.com - February 9 at 3:29 PM
capitalcube.com logoAlder Biopharmaceuticals, Inc. – Value Analysis (NASDAQ:ALDR) : February 8, 2017 (NASDAQ:ALDR)
www.capitalcube.com - February 8 at 3:37 PM
capitalcube.com logoAlder Biopharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ALDR-US : February 7, 2017 (NASDAQ:ALDR)
www.capitalcube.com - February 7 at 3:54 PM
4-traders.com logoALDER BIOPHARMACEUTICALS INC : Change in Directors or Principal Officers (form 8-K) (NASDAQ:ALDR)
www.4-traders.com - February 1 at 1:40 AM
News IconStock Vacillating as Volatility Hits a High Point For Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) - Wall Street Beacon (NASDAQ:ALDR)
wsbeacon.com - January 31 at 3:37 PM
News IconRSI, CCI, and ADX Levels in View for Alder Biopharmaceuticals Inc (ALDR) - Market Point (NASDAQ:ALDR)
mtptnews.com - January 26 at 3:43 PM
News IconInteresting ALDR Put And Call Options For March 17th (NASDAQ:ALDR)
www.stockoptionschannel.com - January 25 at 8:35 PM
News IconConsensus Take: Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) Earnings & Ratings Watch - Aiken Advocate (NASDAQ:ALDR)
aikenadvocate.com - January 25 at 3:32 PM
prnewswire.com logoResearch Reports Coverage on Biotech Stocks -- Genetic Technologies, Alder Biopharma, BioDelivery Sciences, and ... - PR Newswire (press release) (NASDAQ:ALDR)
www.prnewswire.com - January 24 at 3:48 PM
News IconCrunching the Numbers for Alder Biopharmaceuticals Inc (ALDR) - Springdale Times (NASDAQ:ALDR)
springdaletimes.com - January 23 at 3:29 PM
4-traders.com logoInsider Trading Activity Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) – Insider Sold 1,498 shares of Stock (NASDAQ:ALDR)
www.4-traders.com - January 21 at 1:54 AM
News IconAmplified Volatility Spotted in Shares of Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) - Wall Street Beacon (NASDAQ:ALDR)
wsbeacon.com - January 20 at 3:46 PM
News IconAlder BioPharmaceuticals, Inc. (NASDAQ:ALDR):Brokerage Firm Rating Analysis - Highland Mirror (NASDAQ:ALDR)
www.highlandmirror.com - January 19 at 3:48 PM
nasdaq.com logoUPDATE 3-Lilly builds migraine arsenal with $960 mln CoLucid buy (NASDAQ:ALDR)
www.nasdaq.com - January 18 at 8:58 PM
News IconShooting From the Hip, Stock Reaches Most Volatile List: Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) - Wall Street Beacon (NASDAQ:ALDR)
wsbeacon.com - January 18 at 3:57 PM
investors.com logoLilly Regains Key Migraine Drug With $960 Million CoLucid Acquisition (NASDAQ:ALDR)
www.investors.com - January 18 at 3:57 PM
News IconInvestors Priming the Pump as Stock Reaches Most Volatile List: Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) - Wall Street Beacon (NASDAQ:ALDR)
wsbeacon.com - January 17 at 9:11 PM
News IconAlder Biopharmaceuticals Inc ALDR Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:ALDR)
www.bioportfolio.com - January 17 at 10:09 AM
News IconStock Checkup: Technical Watch on Alder Biopharmaceuticals Inc (ALDR) - Sherwood Daily (NASDAQ:ALDR)
sherwooddaily.com - January 16 at 3:26 PM
News IconDrilling Down Into the Charts for Alder Biopharmaceuticals, Inc. (ALDR) - The USA Commerce (NASDAQ:ALDR)
theusacommerce.com - January 13 at 3:50 PM
investors.com logoTrump's 'Disastrous' Pharma View Doesn't Rattle JPMorgan Drug Conference (NASDAQ:ALDR)
www.investors.com - January 13 at 3:50 PM
seekingalpha.com logoAlder Biopharmaceuticals (ALDR) Presents At 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:ALDR)
seekingalpha.com - January 12 at 1:46 AM
News IconStock Getting Tripped Up In Session: Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) - Wall Street Beacon (NASDAQ:ALDR)
wsbeacon.com - January 11 at 8:45 PM
News IconStock Reaching Most Volatile List Today: Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) - Wall Street Beacon (NASDAQ:ALDR)
wsbeacon.com - January 11 at 3:42 PM
News IconReady for an Upsurge? Analysts Chime in on Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) - Prospect Journal (NASDAQ:ALDR)
prospectjournal.com - January 10 at 3:28 PM
investornewswire.com logoCan Shares Of Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) Hit $47? - Investor Newswire (NASDAQ:ALDR)
www.investornewswire.com - January 7 at 8:45 PM
thestreet.com logo[video]Amgen Shares Skyrocket on Surprise Patent Victory, Plus Jim Cramer's View (NASDAQ:ALDR)
www.thestreet.com - January 6 at 3:33 PM
thestreet.com logoHere's Why Teva Shares Are Plummeting (NASDAQ:ALDR)
www.thestreet.com - January 6 at 3:33 PM
investopedia.com logoBlockbuster Potential of Migraine Drugs (AMGN, ALDR) - Investopedia (NASDAQ:ALDR)
www.investopedia.com - January 3 at 3:48 PM
News IconTop Rated Stock With Earnings Growth & Implied Upside: Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) - Prospect Journal (NASDAQ:ALDR)
prospectjournal.com - January 3 at 6:50 AM
finance.yahoo.com logoAlder BioPharmaceuticals to Present at the 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:ALDR)
finance.yahoo.com - January 2 at 4:03 PM
investornewswire.com logoAlder BioPharmaceuticals, Inc. (NASDAQ:ALDR) Strong Buy Recommendations At 7 - Investor Newswire (NASDAQ:ALDR)
www.investornewswire.com - December 31 at 3:25 PM
nasdaq.com logoCommit To Purchase Alder Biopharmaceuticals At $15, Earn 14.9% Annualized Using Options (NASDAQ:ALDR)
www.nasdaq.com - December 30 at 3:28 PM
nasdaq.com logoCommit To Purchase Alder Biopharmaceuticals At $15, Earn 14.9% Annualized Using Options - Nasdaq (NASDAQ:ALDR)
www.nasdaq.com - December 29 at 3:29 PM
publicnow.com logoThe Extraordinary General Shareholders’ Meeting of 22 December 2016 marks a new phase in the Group’s development plan (NASDAQ:ALDR)
www.publicnow.com - December 29 at 3:28 PM
finance.yahoo.com logoMigraine drugs may repeat rheumatoid arthritis success (NASDAQ:ALDR)
finance.yahoo.com - December 23 at 3:32 PM
publicnow.com logoSubscription of one block of 1 million euros under the February 2015 contract for convertible notes with attached warrants (NASDAQ:ALDR)
www.publicnow.com - December 21 at 4:28 PM
News IconChecking the Levels on Shares of Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) - The Business Journal (NASDAQ:ALDR)
belmontbusinessjournal.com - December 20 at 8:38 PM
News IconIndicator Review on Shares of Alder Biopharmaceuticals Inc (ALDR) - StockTalk Daily (NASDAQ:ALDR)
stocktalkdaily.com - December 20 at 8:38 PM
News IconGrowth Story Unfolding for Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) - Prospect Journal (NASDAQ:ALDR)
prospectjournal.com - December 19 at 3:37 PM
News IconEquity Rundown: RSI and CCI Check on Alder Biopharmaceuticals Inc (ALDR) - StockTalk Daily (NASDAQ:ALDR)
stocktalkdaily.com - December 17 at 3:28 PM
News IconEye on Technicals for Alder Biopharmaceuticals Inc (ALDR) - StockTalk Daily (NASDAQ:ALDR)
stocktalkdaily.com - December 16 at 8:36 PM
nasdaq.com logoAlder Biopharmaceuticals (ALDR) Sees Hammer Chart Pattern: Time to Buy? - Nasdaq (NASDAQ:ALDR)
www.nasdaq.com - December 14 at 3:39 PM
finance.yahoo.com logoAlder Biopharmaceuticals (ALDR) Sees Hammer Chart Pattern: Time to Buy? (NASDAQ:ALDR)
finance.yahoo.com - December 14 at 3:38 PM
News IconInvestor Circle: Watching the Numbers on Shares of Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) - Marion Business Daily (NASDAQ:ALDR)
marionbusinessdaily.com - December 13 at 3:29 PM
News IconInvestor Watchlist: Narrowing in on Shares of Alder Biopharmaceuticals Inc (ALDR) - StockTalk Daily (NASDAQ:ALDR)
stocktalkdaily.com - December 10 at 3:26 PM

Social

What is Alder BioPharmaceuticals' stock symbol?

Alder BioPharmaceuticals trades on the NASDAQ under the ticker symbol "ALDR."

Where is Alder BioPharmaceuticals' stock going? Where will Alder BioPharmaceuticals' stock price be in 2017?

9 brokerages have issued twelve-month price targets for Alder BioPharmaceuticals' shares. Their predictions range from $38.00 to $47.00. On average, they anticipate Alder BioPharmaceuticals' stock price to reach $42.50 in the next year.

When will Alder BioPharmaceuticals announce their earnings?

Alder BioPharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February, 21st 2017.

What are analysts saying about Alder BioPharmaceuticals stock?

Here are some recent quotes from research analysts about Alder BioPharmaceuticals stock:

  • According to Zacks Investment Research, "Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and seeks to commercialize therapeutic antibodies. It is developing monoclonal antibodies comprising ALD403, for the prevention of migraine; and Clazakizumab, in the treatment of rheumatoid arthritis and psoriatic arthritis. Alder Biopharmaceuticals Inc. is headquartered in Bothell, Washington. " (2/16/2017)

  • Brean Capital analysts commented, "We anticipate ALD403 US drug sales reaching $1 billion annually well before patent expiration in 2032," analyst Difei Yang wrote in a note.Yang noted that the ALD403 has huge market potential as recent data from Migraine Research Foundation says each year in the United States about 10 million to 14 million adults experience frequent or chronic migraines, leading to nearly $13 billion in lost productivity in the United States alone."A primary advantage of ALDR403 vs. other close-to-market CGRP's is its dosing schedule, which consists of a single IV treatment every 3 months. The remaining 3 CGRP's in late-stage development rely on monthly subcutaneous injections," (9/30/2016)

Who owns Alder BioPharmaceuticals stock?

Alder BioPharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (14.93%), Janus Capital Management LLC (9.82%), State Street Corp (3.50%), Foresite Capital Management III LLC (3.24%), Foresite Capital Management II LLC (1.98%) and Brown Advisory Inc. (0.99%). Company insiders that own Alder BioPharmaceuticals stock include Clay B Siegall, Jeffrey T L Smith, John A Latham, Larry Benedict, Mark James Litton, Randall C Schatzman and Stephen M Dow.

Who sold Alder BioPharmaceuticals stock? Who is selling Alder BioPharmaceuticals stock?

Alder BioPharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Highland Capital Management LP, Allianz Asset Management AG, Fiera Capital Corp, FMR LLC and Franklin Resources Inc.. Company insiders that have sold Alder BioPharmaceuticals stock in the last year include Jeffrey T L Smith, John A Latham, Mark James Litton and Randall C Schatzman.

Who bought Alder BioPharmaceuticals stock? Who is buying Alder BioPharmaceuticals stock?

Alder BioPharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Janus Capital Management LLC, Clough Capital Partners L P, State Street Corp, New Leaf Venture Partners L.L.C., Eventide Asset Management LLC, Foresite Capital Management II LLC and Paulson & CO. Inc..

How do I buy Alder BioPharmaceuticals stock?

Shares of Alder BioPharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Alder BioPharmaceuticals stock cost?

One share of Alder BioPharmaceuticals stock can currently be purchased for approximately $21.75.

Alder BioPharmaceuticals (NASDAQ:ALDR) Chart for Wednesday, February, 22, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Alder BioPharmaceuticals (NASDAQ:ALDR)

Earnings History Chart

Earnings by Quarter for Alder BioPharmaceuticals (NASDAQ:ALDR)

Dividend History Chart

Dividend Payments by Quarter for Alder BioPharmaceuticals (NASDAQ:ALDR)

Last Updated on 2/22/2017 by MarketBeat.com Staff